PT - JOURNAL ARTICLE AU - Ye, Zhenbang AU - Huang, Ning AU - Fu, Yongliang AU - Tian, Rongle AU - Wang, Liming AU - Huang, Wenting TI - Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity of DLBCL Patients AID - 10.1101/2023.10.04.23296534 DP - 2024 Jan 01 TA - medRxiv PG - 2023.10.04.23296534 4099 - http://medrxiv.org/content/early/2024/03/26/2023.10.04.23296534.short 4100 - http://medrxiv.org/content/early/2024/03/26/2023.10.04.23296534.full AB - Background Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant B-cell lymphoma. Although various treatments have been developed, the limited efficacy calls for more and further exploration of its characteristics.Methods Datasets from Gene Expression Omnibus (GEO) database were used for identifying the tumor purity of DLBCL. Survival analysis was employed for analyzing the prognosis of DLBCL patients. Immunohistochemistry was conducted to detect the important factor that influenced the prognosis. Drug sensitive prediction was performed to evaluate the value of the constructed model.Results VCAN, CD3G and C1QB were identified as three key genes that impacted the outcome of DLBCL patients both in GEO datasets and samples from our center. Among them, VCAN and CD3G+ T cells were correlated with favorable prognosis, and C1QB was correlated with worse prognosis. The ratio of CD68+ macrophages and CD8+ T cells was associated with better prognosis. In addition, CD3G+ T cells ratio was significantly correlated with CD68+ macrophages, CD4+ T cells and CD8+ T cells ratio, indicating it could play an important role in the anti-tumor immunity in DLBCL. The riskScore model constructed based on the RNASeq data of VCAN, C1QB and CD3G work well in predicting the prognosis and drug sensitivity.Conclusion VCAN, CD3G and C1QB were three key genes that influenced the tumor purity of DLBCL, and could also exert certain impact on drug sensitivity and prognosis of DLBCL patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by Shenzhen High-level Hospital Construction Fund and CAMS Innovation Fund for Medical Sciences (CIFMS) (2022-I2M-C&T-B-062). The funders had no role in study design, data collection and analysis, interpretation of data, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was designed according to the Declaration of Helsinki and approved by the institutional ethics committee of Cancer Hospital Chinese Academy of Medical Sciences.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe GEO datasets can be obtained from https://www.ncbi.nlm.nih.gov/gds/?term=. Due to the nature of this study, the data of CHCAMS cohort can be accessed from Dr. Wenting Huang upon reasonable request. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53786